Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 49.92 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 9.18 | 27.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +112.9% | |
| P/B Ratio | 0.13 | 0.75 | 0.77 | 0.52 | 0.36 | 0.68 | 0.42 | 0.43 | 0.45 | 0.62 | 0.47 | 0.72 | 0.48 | 0.30 | 0.44 | 0.93 | 1.27 | 1.86 | 2.00 | 2.95 | 1.96 |
| — | +10.5% | +85.5% | +22.7% | -19.5% | +9.3% | -10.7% | -40.7% | -5.2% | +104.5% | +6.8% | -22.7% | -62.5% | -83.8% | -78.1% | -68.5% | -34.9% | +62.0% | +39.1% | +104.2% | -22.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 155.77 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 32.65 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 35.62 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18.8% | -284.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -96.5% | -64.5% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18.5% | -289.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -96.5% | -74.7% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -67.6% | -16.9% | -16.4% | -13.5% | -22.7% | -22.1% | -21.2% | -16.2% | -14.4% | -13.6% | -12.1% | -13.1% | -16.2% | -23.0% | -12.8% | -11.1% | -9.8% | -7.2% | -7.5% | 1.5% | -6.1% |
| — | +23.5% | +22.5% | +16.6% | -57.6% | -62.3% | -74.9% | -24.1% | +10.7% | +40.7% | +5.6% | -18.1% | -65.0% | -219.4% | -72.0% | -835.4% | -61.2% | -14.5% | -59.6% | +112.2% | +23.1% | |
| ROA | -56.6% | -13.6% | -13.5% | -11.2% | -18.3% | -17.7% | -17.6% | -13.7% | -12.3% | -11.8% | -10.6% | -11.2% | -13.4% | -19.5% | -11.1% | -9.7% | -8.7% | -6.4% | -6.7% | 1.4% | -5.3% |
| — | +23.0% | +23.7% | +18.4% | -48.8% | -49.5% | -65.6% | -22.5% | +7.9% | +39.4% | +4.3% | -15.2% | -53.5% | -203.7% | -65.4% | -814.7% | -64.4% | -20.7% | -70.6% | +113.9% | +9.9% | |
| ROIC | -64.9% | -26.1% | -15.4% | -12.8% | -20.7% | -20.0% | -18.4% | -15.1% | -17.0% | -32.2% | -80.2% | -73.9% | -73.3% | -87.6% | -45.8% | -43.9% | -42.1% | -30.9% | -31.3% | 7.0% | -25.3% |
| — | -30.5% | +16.6% | +15.2% | -22.2% | +37.9% | +77.0% | +79.6% | +76.8% | +63.3% | -75.2% | -68.3% | -74.0% | -183.9% | -46.2% | -724.3% | -66.3% | -28.6% | -46.4% | +118.2% | -42.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.12 | 0.11 | 0.10 | 0.09 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | 0.08 | 0.08 | 0.12 | 0.11 | 0.09 | 0.09 | 0.07 | 0.07 | 0.08 | 0.07 | 0.07 |
| — | -17.2% | -7.1% | -1.4% | +0.2% | +65.5% | +41.5% | +30.0% | -24.9% | -23.2% | -14.1% | -12.3% | +71.0% | +63.8% | +24.1% | +33.4% | +4.1% | -27.7% | -15.1% | -26.3% | -64.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.07 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.47 | 6.09 | 6.71 | 7.65 | 7.47 | 5.62 | 7.48 | 9.34 | 9.29 | 10.64 | 12.75 | 14.34 | 8.41 | 9.40 | 11.08 | 12.98 | 13.25 | 16.59 | 16.10 | 27.07 | 17.31 |
| — | +8.3% | -10.3% | -18.0% | -19.5% | -47.1% | -41.4% | -34.9% | +10.4% | +13.1% | +15.2% | +10.5% | -36.5% | -43.3% | -31.2% | -52.1% | -23.5% | +67.0% | +56.0% | +197.5% | +287.8% | |
| Quick Ratio | 7.47 | 6.09 | 6.71 | 7.65 | 7.47 | 5.62 | 7.48 | 9.34 | 9.29 | 10.64 | 12.75 | 14.34 | 8.41 | 9.40 | 11.08 | 12.98 | 13.25 | 16.59 | 16.10 | 27.07 | 17.31 |
| — | +8.3% | -10.3% | -18.0% | -19.5% | -47.1% | -41.4% | -34.9% | +10.4% | +13.1% | +15.2% | +10.5% | -36.5% | -43.3% | -31.2% | -52.1% | -23.5% | +67.0% | +56.0% | +197.5% | +287.8% | |
| Interest Coverage | -3243.53 | -860.70 | -963.32 | -879.17 | -1270.50 | -2237.00 | — | — | -28726.00 | -30477.00 | — | -14007.00 | — | -49884.00 | -8099.75 | -1624.32 | -1148.04 | -1221.00 | -1251.11 | 257.56 | -621.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACET stock.
Adicet Bio, Inc.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Adicet Bio, Inc.'s business trajectory between earnings reports.